Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion

“…Some studies have reported that patients with EGFR mutations were associated with a better prognosis compared with those without EGFR mutations, but most of them were based on the use of EGFR-TKI [20][21][22][23]. Two studies from Tetsuya Isaka et al [24] and Masaya Yotsukura et al [25] have reported patients with EGFR mutations in operable early-stage lung adenocarcinoma had a better RFS because of its higher incidence of lepidic growth pattern, adenocarcinoma in situ and minimally invasive adenocarcinoma, which rarely recur after resection of the lung when compared with those without EGFR mutations, but there was no significant difference in OS. However whether the histological subtype of lung adenocarcinoma is a prognostic factor remains controversial [26][27][28].…”

Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma

“…Second, there may be histopathologic differences between two common EGFR mutations. Although one previous study showed that lepidic adenocarcinoma tends to be associated with a greater frequency of EGFR mutations [24], some studies have reported that Ex21 mutations were more frequent in lepidic adenocarcinoma than WT EGFR or other types of EGFR mutations, including Ex19 [17,25]. In this study, we analyzed the differences in subtypes of invasive adenocarcinoma between two common mutation groups using available data (152 patients in the Ex19 group and 212 patients in the Ex21 group); however, the difference was not significant (p ¼ 0.190).…”

“…Supplemental Table 1 shows a summary of previous studies evaluating differences in recurrence-free survival (RFS), DFS, and OS between patients with Ex19 and Ex21 among patients with surgically resected lung cancer [4,[11][12][13][14][15][16][17]. Okamoto and colleagues [15] reported that patients with Ex19 had significantly shorter DFS than patients with Ex21 among patients with surgically resected stage I through stage III lung adenocarcinoma, although two other recent articles did not show significant differences among patients with early stage lung cancer [16,17]. These previous studies were smaller, and the analyses were conducted at a single institution; therefore, in this study, we collected a large number of cases from five institutions and analyzed only patients who underwent lobectomy, to reduce bias.…”

Frecuencia de mutación T790M determinada por biopsia líquida en pacientes con cáncer pulmonar de células no pequeñas después de la progresión a inhibidores de tirosina cinasa contra EGFR en primera línea

“…El principal mecanismo de resistencia adquirida informado es la mutación secundaria T790M en el exón 20, en el gen EGFR. 14 Varios estudios han examinado los mecanismos y la frecuencia de la resistencia a EGFR-TKI; sin embargo, esto no había sido explorado en pacientes latinoamericanos. En una cohorte de Japón en 2016 por Ko et al, cuyo objetivo fue analizar las frecuencias de la resistencia adquirida a EGFR-TKI en T79M en pacientes japoneses con CPCNP, se observó una frecuencia de 34%.…”

“…Afatinib difiere de gefitinib y erlotinib, debido a su unión irreversible y al EGFR, y al receptor del factor de crecimiento epidérmico humano 2-4 (su 2, su 3, su 4); los estudios no mostraron una diferencia significativa al compararse entre ellos. 14,15 Recientemente, dacomitinib, otro inhibidor de tirosina cinasa de segunda generación (TKI), en comparación con gefitinib, mostró ser superior 5.5 meses en SLP (14.7 contra 9.2 meses), pero de nuevo con toxicidades aumentadas. Afatinib podría tener un papel importante en pacientes con mutaciones poco comunes; sin embargo, los informes de su actividad han sido inconsistentes hasta el momento.…”